Aethlon Medical shares are trading higher after the company announced that it received granted ethics committee approval for Hemopurifier cancer treatment. Also, the European Commission recommended extending the indication of the smallpox and mpox vaccine to adolescents.
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical's stock is rising following ethics committee approval for its Hemopurifier cancer treatment. Additionally, the European Commission has recommended extending the smallpox and mpox vaccine to adolescents.
September 20, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aethlon Medical's stock is trading higher due to the ethics committee's approval of its Hemopurifier cancer treatment, which is a positive regulatory milestone.
The approval from the ethics committee is a significant regulatory step for Aethlon Medical's Hemopurifier cancer treatment, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90